DSwiss (DQWS) Stock Price, News & Analysis

DSWISS Inc (DQWS) is a manufacturing-sector company that operates in the field classified as All Other Miscellaneous Chemical Product and Preparation Manufacturing. According to company disclosures, DSWISS focuses on biotech-nutraceutical products, medical consumables, and beauty-related supplies, with activities that span product development, manufacturing support, and distribution.

The company states that it sells medical consumable supplies, food supplements, skincare, and related beauty products in Malaysia and around the ASEAN region through its Malaysia and Hong Kong subsidiaries. In addition to selling finished goods, DSWISS positions itself as a provider of turnkey private label manufacturing services for nutraceutical and skincare OEM/ODM products, working with clients that want to bring their own branded formulations to market.

Business activities and services

DSWISS describes itself as a premier biotech-nutraceutical, medical consumables supply, and beauty supplies company. Its activities include managing custom formulation of scientifically referenced and naturally effective products, sourcing raw materials, overseeing production, and implementing quality control. The company also highlights its involvement in stability and safety testing, clinical testing by third-party laboratories, packaging, and shipping processes, including import and export handling.

The manufacturer facilities used for DSWISS-related products are stated to be compliant with several standards and certifications: GMP (Good Manufacturing Practice), FDA (Food and Drug Association), HACCP (Hazard Analysis and Critical Control Point), JAKIM HALAL, and Mesti. These references indicate an emphasis on regulated production environments and adherence to health, safety, and religious-compliance frameworks relevant to its markets.

Geographic footprint and market focus

Based on available information, DSWISS conducts a significant portion of its commercial activity in Malaysia and across the ASEAN region, supported by subsidiaries in Malaysia and Hong Kong. Its product mix centers on medical consumables, nutraceutical food supplements, skincare, and other beauty-related items, aligning with its classification in the broader chemical product and preparation manufacturing space.

Strategic collaboration and product portfolio context

In a disclosed announcement, DSWISS reported a global partnership with Japan-listed company RECOMM Co., Ltd. for an exclusive arrangement involving an air and surface purifier and sterilizer branded as RESPR in the territory of Malaysia. The collaboration is described as combining DSWISS’s sales and marketing expertise with RECOMM’s multi-national business scale. The RESPR device is characterized as a "COVID-19 killer" air and surface purifier and sterilizer that utilizes NCC technology to generate natural oxidants such as hydrogen peroxide, which are described as eliminating harmful microorganisms while being innocuous to humans.

The announcement notes that the RESPR sterilization device achieved certified results in reducing 99.9% of the SARS CoV-2 virus, which the company presents as a key attribute during the COVID-19 pandemic. This collaboration illustrates how DSWISS extends its activities beyond traditional nutraceutical and skincare products into air and surface sterilization solutions through partnerships.

Corporate structure and governance note

DSWISS Inc is incorporated in Nevada, as reflected in its SEC filings. In a reported Form 8-K, the company disclosed a change in its board composition. The filing states that on October 1, 2025, director Sui Ting Wong tendered a resignation as director of the company, and following that resignation, Leong Ming Chia became the sole director of DSWISS Inc. The same filing identifies the principal executive offices as being located in Kuala Lumpur, Malaysia, indicating that while the company is incorporated in Nevada, its executive operations are based in Malaysia.

Operational capabilities

According to the company’s own description, DSWISS’s professionals manage multiple stages of the product lifecycle for nutraceutical and skincare OEM/ODM products. This includes:

• Custom formulation of scientifically referenced and naturally effective products
• Sourcing of raw materials
• Production oversight
• Quality control procedures
• Stability and safety testing
• Clinical testing carried out by third-party laboratories
• Packaging and shipping, including import and export processes

This combination of activities positions DSWISS as a partner for brands seeking private label nutraceutical and skincare products produced under recognized regulatory and quality frameworks.

Regulatory and quality framework

The company emphasizes that its associated manufacturing facilities adhere to GMP, FDA, HACCP, JAKIM HALAL, and Mesti standards. These frameworks cover good manufacturing practices, food and drug oversight, hazard analysis and critical control points for food safety, Islamic dietary compliance, and local regulatory requirements. By highlighting these certifications, DSWISS underscores a focus on structured quality systems and compliance relevant to health-related consumables and skincare products.

Position within the manufacturing sector

Within the Manufacturing sector, DSWISS falls under the category of All Other Miscellaneous Chemical Product and Preparation Manufacturing. Its activities in biotech-nutraceuticals, medical consumables, and beauty supplies connect chemical product preparation with consumer health and personal care markets. The company’s OEM/ODM turnkey services indicate that it not only markets its own product lines but also supports other brands in bringing formulated products to market under private labels.

Stock and regulatory context

DSWISS Inc’s shares trade under the symbol DQWS. As an SEC-reporting company incorporated in Nevada, it files regulatory documents such as Form 8-K to report material corporate events. These filings, together with company communications, provide investors and observers with information about governance changes, strategic collaborations, and other significant developments.